Frank Steven 4

What Happened

• Frank Steven, a non-employee director of BioCryst Pharmaceuticals, received automatic director compensation on June 11, 2026: 15,294 restricted stock units (RSUs) and 33,540 stock-option grants. Both awards were reported as acquired at $0.00 (grant), so no cash changed hands in the reported transactions.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 15, 2026 (filed within the typical 2-business-day Form 4 window).
• RSUs: 15,294 shares granted at $0.00 (Footnote F1). These RSUs vest on the first anniversary of the grant per the Director Compensation Policy.
• Options/derivative: 33,540 option grants reported at $0.00 (Footnote F2) as automatic non-employee director stock-option awards under the Director Compensation Policy.
• Shares owned after transaction: not specified in the supplied filing excerpt.
• No 10b5-1 plan, tax withholding, or sale activity indicated in this filing excerpt.

Context

• These are routine, non-cash compensation awards for a non-employee director under the company’s director compensation policy, not an open-market purchase or sale. RSUs typically represent a delayed equity grant (vesting schedule noted), and option grants give the right to buy shares later if exercised under the plan terms. Such awards are standard director pay and should be interpreted as compensation rather than a direct market sentiment signal.